BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/18/2021 6:37:38 AM | Browse: 253 | Download: 314
Publication Name World Journal of Cardiology
Manuscript ID 65949
Country/Territory Japan
Received
2021-03-21 01:34
Peer-Review Started
2021-03-21 01:37
To Make the First Decision
Return for Revision
2021-05-06 00:00
Revised
2021-05-11 09:51
Second Decision
2021-07-23 03:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2021-07-23 06:44
Articles in Press
2021-07-23 06:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2021-09-13 08:16
Publish the Manuscript Online
2021-09-18 06:37
ISSN 1949-8462 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Minireviews
Article Title Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy
Manuscript Source Invited Manuscript
All Author List Ryo Naito and Takatoshi Kasai
ORCID
Author(s) ORCID Number
Ryo Naito http://orcid.org/0000-0003-3348-2125
Takatoshi Kasai http://orcid.org/0000-0001-5747-7668
Funding Agency and Grant Number
Corresponding Author Takatoshi Kasai, MD, PhD, Associate Professor, Department of Cardiovascular Biology and Medicine, Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine; Sleep and Sleep Disordered Breathing Center, Juntendo University Hospital, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421, Japan. kasai-t@mx6.nisiq.net
Key Words Sodium glucose cotransporter 2 inhibitors; Heart failure; Clinical trials; Potential mechanisms; Diuretics
Core Tip Sodium glucose cotransporter 2 inhibitors are newly approved by the Food and Drug Administration as treatment choice for heart failure based on evidence from several large-scale clinical trials demonstrating reduction in cardiovascular outcomes, especially hospitalization for heart failure or cardiovascular death. The background of the approval and potential mechanisms are discussed in this review. As well, summary of available evidence from clinical trials and ongoing trials examining beneficial effects of the agents are written.
Publish Date 2021-09-18 06:37
Citation Naito R, Kasai T. Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy. World J Cardiol 2021; 13(9): 464-471
URL https://www.wjgnet.com/1949-8462/full/v13/i9/464.htm
DOI https://dx.doi.org/10.4330/wjc.v13.i9.464
Full Article (PDF) WJC-13-464.pdf
Full Article (Word) WJC-13-464.docx
Manuscript File 65949_Auto_Edited-JPY.docx
Answering Reviewers 65949-Answering reviewers.pdf
Audio Core Tip 65949-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 65949-Conflict-of-interest statement.pdf
Copyright License Agreement 65949-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 65949-Language certificate.pdf
Peer-review Report 65949-Peer-review(s).pdf
Scientific Misconduct Check 65949-Scientific misconduct check.pdf
Scientific Editor Work List 65949-Scientific editor work list.pdf